Sequence 2 from Patent US 20120328692

General Information


DRACP ID  DRACP01471

Peptide Name   Sequence 2 from Patent US 20120328692

Sequence  WYANFEKLLR

Sequence Length  10

UniProt ID  Not available

PubChem CID  Not available

Origin  Synthetic construct

Type  Synthetic peptide

Classification

  

Active ACP



Activity Information


Hemolytic Activity  Not available

Normal (non-cancerous) Cytotoxicity  Not available

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Anticancer



Structure Information


PDB ID  Not available

Predicted Structure  DRACP01471

Helicity  Not available

Linear/Cyclic  Not available

Disulfide/Other Bond  Not available

N-terminal Modification  Not available

C-terminal Modification  Not available

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C65H94N16O15

Absent amino acids  CDGHIMPQSTV

Common amino acids  L

Mass  150027

Pl  9.3

Basic residues  2

Acidic residues  1

Hydrophobic residues  5

Net charge  1

Boman Index  -1710

Hydrophobicity  -54

Aliphatic Index  88

Half Life 
  Mammalian: 2.8 hour
  Yeast: 3 min
  E.coli: 2 min

Extinction Coefficient cystines  6990

Absorbance 280nm  776.67

Polar residues  2

Amino acid distribution



Literature Information


Literature 1

Pubmed ID Not available

Title  Not available

Doi Not available

Year  Not available

Patent

Patent ID US 2012/0328692 A1

Patent Title  Potent D-peptide antagonists of mdm2 and mdmx for anticancer therapy.

Other Iinformation  Granted Patent Family: 8s / 8ex; Family Jurisdictions: CN, DK, US, EP, ES; Legal Status: Active; Application No: 16168397; Filed:May 4, 2016; Published: Jul 17, 2019; Earliest Priority: May 7, 2015; Granted: Jul 17, 2019

Other Published ID  Not available




DRACP is developed by Dr.Zheng's team.